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Abstract. Previous phase I DNA-vaccine based clinical trials 
using Mammaglobin-A (Mam-A), a human breast tumor 
associated antigen (TAA), demonstrated that this agent was 
safe and efficient at treating patients with stage IV breast 
cancer. The long-term success of cancer vaccines is limited 
by the diminished expression of human leukocyte antigen 
(HLA) class I molecules in the tumor microenvironment. The 
current study assessed the impact of various selenocompounds 
on the expression of HLA class I molecules in THP-1 cells, 
an apparent proficient antigen that presents a human mono-
cyte-like cell line, and their eventual activation of MamA2.1 
(HLA‑A2 immunodominant epitope of Mam‑A) specific cyto-
toxic CD8+ T lymphocytes (CTLs). The results revealed that, 
following treatment with methylselenol producing compounds 
[methylselenic acid (MSA) and dimethylselenide (DMDSe)], 
the expression of HLA class-I was increased and components 
involved with the antigen presentation machinery of THP-1 
cells were upregulated. Furthermore, CTLs activated by 
MamA2.1 peptide presenting THP-1 cells, pre-treated with 
MSA and DMDSe, demonstrated an enhanced cytotoxicity 
in HLA-A2+/Mam-A+ AU565 and UACC-812 breast cancer 
cell lines when compared with CTLs activated by THP-1 cells 
without drug treatment. However, no significant cytotoxicity 
was observed under similar conditions in HLA-A2+/Mam-A- 
MCF-7 and MDA-MB-231 breast cancer cell lines. The 
results indicated that treatment with methylselenol producing 
compounds retained antigen-dependent activation of CD8+ 
T cells. The data of the current study demonstrated that MSA 
and DMDSe potentiated effector cytotoxic responses following 
TAA specific activation of CTLs, indicating their future role 
as vaccine adjuvants in cancer immunotherapy.
Introduction
Tumors adopt various immune escape strategies to avoid 
recognition and elimination by cytotoxic CD8+ T lympho-
cytes (CTLs) (1). A major mechanism by which tumors 
escape immune recognition is by downregulating their 
surface expression of human leukocyte antigen (HLA) 
class I molecules. A major explanation for the disappointing 
outcome from DNA and peptide-based anti-cancer vaccines 
is that the minimal tumoral expression of HLA class I 
molecules do not allow for the vaccine activated CTLs to 
exert their cancer eliminating cytotoxic effect in the tumor 
microenvironment (2). Similarly, decreased HLA expression 
is also considered to play a deleterious role in the favorable 
clinical outcomes of immune checkpoint inhibitor based 
cancer immunotherapeutic strategies. A decreased HLA 
class I expression is noted in various solid organ tumors 
including breast cancers (3). Hence, there is an important 
need to develop novel approaches to enhance HLA class I 
expression to overcome tumor immune escape and promote 
tumor rejection. Further, potential HLA class I recovery in 
the tumor microenvironment will complement the clinical 
outcome of various anti-tumor immunotherapeutic strategies 
including vaccine based approaches.
Active metabolite derivatives of Selenium (Se) have been 
suggested to exert an anti-carcinogenic effect on many solid 
organ tumors such as prostate and breast cancer (4). Clinical 
interventional studies demonstrated that a supra-nutritive 
intake of Se has positive effects in the prevention of several 
solid organ cancers (5). The two key metabolites of Se (Fig. 1A), 
hydrogen selenide (H2Se), derived mainly from inorganic sele-
nocompounds such as selenate or selenite, and methylselenol 
(CH3SeH), derived from organic selenocompounds, such as 
methyl selenic acid (MSA) and dimethylselenide (DMDSe), 
have been shown to be crucial for the biological function of 
these selenocompounds (6,7). While the exact mechanisms 
of action of this anti-carcinogenic effect of selenium deriva-
tives are unknown, several studies have suggested that the 
Se metabolite, methylselenol, is the active Se compound for 
anti-carcinogenic effects while remaining non-cytotoxic on 
normal terminally differentiated cells. Murine tumor studies 
have shown that combined treatment of MSA with paclitaxel 
reduced tumor growth of tumor xenografts with triple negative 
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breast cancer cells (TNBC) compared to paclitaxel treatment 
alone (8).
Mammaglobin-A (Mam-A) is a human breast tumor-asso-
ciated antigen (TAA) expressed in 40-80% of primary and 
metastatic breast cancers (9-13). Previously, we have demon-
strated that Mam-A based vaccination to stage-IV human breast 
cancer patients was safe and efficient in increasing progression 
free survival in vaccinated patients. Murine and in vitro studies 
have demonstrated that HLA-A2-restricted MamA2.1 peptide 
(amino acids 83‑92 of Mam‑A, LIYDSSLCDL) exerted specific 
immunodominance towards effector cytotoxic activation 
of naïve CD8+ T lymphocytes (14,15). While we have shown 
that following Mam-A vaccination there was some increase in 
the frequency of MamA2.1+CD8 T cells, strategies to further 
enhance HLA class I expression will provide an additional 
adjuvant methodology to enhance vaccine efficiency. Therefore, 
in this communication, we studied the role of selenium 
compounds towards increasing the cytotoxic efficiency of 
HLA-A2 restricted Mam-A epitope (MamA2.1) activated CTLs 
on Mam-A expressing human breast cancer cells.
Materials and methods
Cell lines and healthy human CD8+ T lymphocytes. The 
human breast cancer cell lines were selected based on the 
specific expression of antigen presenting class I HLA-A2 
molecule and expression of tumor specific antigen, mamma-
globin-A. The following cell lines: MAM-A+/HLA-A2+ 
(AU565 and UACC-812) and MAM-A-/HLA-A2+ (MCF-7 and 
MDA-MB-231), and human monocyte-like HLA-A2+ cell line, 
THP-1 cells, were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). Human CD8+ T cells 
from HLA-A2+ healthy subjects were obtained from StemCell 
Technologies (Cambridge, MA, USA). All cell cultures and 
incubations were performed as per provider's recommenda-
tions and described by us before (16). Briefly, cell were cultured 
in RPMI‑1640 medium at 37˚C in 5% CO2 incubator until they 
were 80% confluent. The presence of Mam‑A and HLA‑A2 
expression in the breast cancer cell lines was confirmed by 
western blot analysis (data not shown). The selenocompounds, 
methylseleninic acid (MSA), dimethylselenide (DMDSe) and 
selenomethionine (SeMet) were obtained from Sigma-Aldrich; 
Merck KGaA, Darmstadt, Germany. The THP-1 cells were 
cultured in 24 well plates, 1x105 per well and stimulated with 
respective selenocompounds (5 µM) for 24 h. These cells were 
later used for various experiments detailed below. For MamA2.1 
peptide stimulation (Peptide 2.0 Inc, Chantilly, VA), CD8+ T 
lymphocytes (1x106) were cultured in 2 ml of supplemented 
RPMI-1640 media in 24-well plates in the presence of irradi-
ated (5,000 rads) THP-1 cells (1x106) loaded with Mam-A2.1 in 
the presence of β2 m (3 µg/ml), CD3 (500 ng/ml), CD28 mAb 
(500 ng/ml) and recombinant human IL-2 (20 U/ml). The CD8+ 
T lymphocytes were isolated by immunomagnetic separation 
(MACS Miltenyi Biotec, San Diego, CA) and the resulting 
purity was verified to be >95%. The MamA2.1 peptide was 
custom synthesized by Peptide 2.0 Inc. (Chantilly, VA) and 
purified on HPLC column to >95% purity.
High‑performance liquid chromatography. The supernatant from 
cell cultures were treated with methanol (1:1 final concentration) 
and injected into the HPLC system. The Agilent 1100 HPLC 
system was comprised of isocratic pump (G1310A) and an auto 
sampler (G1313A). The Gemini C18 (3 µM, 110 Å, 50x1 mm 
inner diameter) columns were utilized for chromatography. 
The mobile phase was 0.1% formaldehyde in 40% methanol. 
The flow rate was 100 µl/min. Injection volumes were 10 µl. 
Data were analyzed with Chemstation software.
Cytotoxicity assay. The cytotoxic efficiency of peptide‑activated 
CD8+ T cells was investigated by its ability to lyse the target 
breast cancer cells by non-irradiative LDH release assay 
(Promega Corporation, Madison, WI, USA) and and MTT assay 
(Life Technologies; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA). The breast cancer cells (1x104 cells) in 100 µl of 
complete medium at were plated in triplicate cultures in round 
bottom 96-well plates in the presence of varying numbers 
of CD8+ T cells (6.25:1 to 50:1) and incubated at 37˚C. The 
percentage specific lysis was calculated as follows: [(experi-
mental LDH release-spontaneous LDH release)/(maximum 
LDH release-spontaneous LDH release)] x100.
Flow cytometry. The HLA-A2 expression in cells were 
analyzed by flow cytometry using appropriated primary 
(BB7.2, BioLegend, San Diego, CA, USA) and FITC-labelled 
secondary antibody. Samples were analyzed using a FACS 
Calibur/LSRII flow cytometer (BD Biosciences, Franklin 
Lakes, NJ, USA). Data were analyzed using BD FACSDiva 
software. Gates were set according to isotype controls.
ELISA. The secretory extracellular IFNγ in the cell supernatant 
was quantitated by ELISA as per the manufacturer's protocol 
(R&D Systems, Minneapolis, MN, USA; catalog# DY285B). 
Quantification was performed with a standard curve using 
the manufacturer provided standards. Detection at 450 nm 
was performed using EMax Plus spectrophotometer and data 
analysis was carried out using software provided by the manu-
facturer (Molecular Devices, Sunyvale, CA, USA).
Western blotting. Total proteins were extracted from cells with 
lysis buffer for western blot analysis as previously described. 
Total proteins were separated on a 4-12% sodium dodecyl 
sulfate-polyacrylamide gradient gel and transferred onto a 
nitrocellulose membrane. All primary and secondary Abs 
were obtained from Abcam (Cambridge, MA, USA) or Santa 
Cruz Biotechnology, Inc. (Dallas, TX, USA). The following 
specific primary antibodies to TAP-1 (sc-376796, Santa 
Cruz Biotechnology, Inc., 1:200), TAP-2 (sc-515576, Santa 
Cruz Biotechnology, Inc., 1:200), LMP-2 (ab3328, Abcam, 
1:500), LMP-7 (ab3329, Abcam, 1:500), tapasin (ab196764, 
Abcam, 1:500), β2-microglobulin (sc-515576, Santa Cruz 
Biotechnology, Inc., 1:200) and β-actin (sc-8432, Santa Cruz 
Biotechnology, Inc., 1:200). The following specific secondary 
antibodies were used based the species of the primary anti-
body: Goat anti-mouse-HRP (ab205718, Abcam, 1:2,500) and 
goat anti-rabbit-HRP (ab205718, Abcam, 1:2,500). The trans-
ferred and probed nitrocellulose membranes were developed 
using the chemiluminescence kit (EMD Millipore, Billerica, 
MA, USA) and analyzed on using Bio-Rad Universal Hood II 
(Hercules, CA, USA). Morphometric analysis was done using 
the software provided by the company.
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Reverse transcription‑quantitative PCR (RT‑qPCR). Expression 
profiles of genes at mRNA level in the breast cancer cell lines 
were analyzed using the SyBr-green detection based RT-qPCR 
primers (Table I), obtained from Integrated DNA Technologies 
(San Jose, CA, USA). Briefly, total RNA was extracted from 
106 cells using TRIzol reagent (Sigma-Aldrich; Merck KGaA) 
and analyzed as mentioned previously. The cycling conditions 
consisted of an initial denaturation of 95˚C for 15 min, followed 
by 40 cycles of 95˚C for 30 sec, followed by 61˚C for 1 min. The 
final reaction volume of 50 µl using BioRad CFX96 (Hercules) 
and analyzed by 2-ΔΔCq method (17).
Statistical analysis. Data are expressed as mean ± SEM from 
four independent studies. Significant differences between 
groups were assessed using Tukey HSD pair-wise comparisons 
for two groups and one-way ANOVA for multiple compari-
sons. A P‑value of <0.05 was considered significant.
Results
Enhanced HLA class I expression following treatment with 
methylselenol producing selenocompounds. As upregula-
tion of HLA class I molecules in the tumor-infiltrating 
immune cells is considered critical for cancer immuno-
therapy, we first examined the potential impact of the three 
selenocompounds, namely methylseleninic acid (MSA), 
dimethyldiselenide (DMDSe) and selenomethionine (SeMet), 
towards modulation of the surface expression of HLA class I 
molecules on THP-1 cells. As the metabolite methylselenol 
is volatile, we investigated the production of dimethylselenol 
(DMSe; Fig. 1A) following treatment with various selenium 
compounds (18,19). We first tested for DMSe production by 
THP-1 cells following treatment with selenocompounds for 
72 h. As shown in Fig. 1B, there was an enhanced DMSe 
production following treatment with MSA and DMDSe, while 
there was no production of DMSe following treatment with 
SeMet. We next tested the cell surface expression of HLA-A2 
on THP-1 cells following treatment with selenocompounds. 
As shown in Fig. 1C-F, DMDSe (2.5 µM) induced a 2.4-fold 
increased expression of HLA-A2 (from 29.8±4.3%, without 
treatment, to 71.7±9.1% following DMDSe treatment, P<0.05) 
on THP-1 cells. Further, MSA (2.5 µM) induced a 2.3-fold 
increased expression of HLA-A2 molecules, while SeMet 
(1-50 µM) did not induce any change in HLA-A2 expression 
on THP-1 cells. These data suggest that MSA and DMDSe 
induced enhanced expression of HLA class I molecules which 
could have a critical adjuvant role in antigen presentation, 
eventually leading to potential immune mediated elimination 
of tumor cells following anti-tumor vaccination.
Upregulation of antigen presenting machinery following 
treatment with methyl selenol producing selenocompounds. 
To determine the molecular mechanisms leading to the 
enhanced upregulation of the HLA-A2 surface expression 
following treatment with selenocompounds, we analyzed the 
changes in the expression of molecules involved in the surface 
expression of HLA class I molecules, also known as antigen 
presentation machinery (APM). As shown in Fig. 2, treatment 
with MSA and DMDSe increased the protein and mRNA tran-
script levels of key APM components, namely, TAP-1, TAP-2, 
LMP-2, LMP-7, tapasin and β2-microglobulin in THP-1 cells. 
However, SeMet treatment did not induce the expression of 
the APM components. These data demonstrate that the MSA 
and DMDSe induced the APM which has a potential to induce 
Table I. Primer sequences used for reverse transcription-quantitative PCR.
    Product
Gene  Forward (5'-3') Reverse (5'-3') Acc. no.  lenght (bp)
Tap1 TGCCTAAGAAGCTGGGAAAA GTAAGCCAAGGCCTCCTTCT NM_013683.2 203
Tap2 CGGTGCTAAAGGAGATCCAG CCATCACCCTCCGTATGACT NM_011530.3 204
LMP2 TCTTCTGTGCCCTCTCAGGT TGGTCCCAGCCAGCTACTAT NM_013585.2 193
LMP7 GGAACGCATCTCCGTGTCTG CTGCCGGTAACCACTGTCCA NM_010724.2 223
Tapasin ACACTGCGAGATGAGCCGCTTC TGAGGACGGTCAGCACCACTGT NM_009318.2 221
B2m GCCGAACATACTGAACTGCT GCCATACTGGCATGCTTAAC NM_009735.3 207
Jak1 CCGCATGAGGTTCTACTTTACC  TCAAATCATACTGTCCCTGTGC NM_146145.2 179
Jak2 GCAGATTCATTCAGCAATTCAG CGTCCTGTTCTGTCAGTGTCTC NM_008413.3 240
Stat1 GACACCTGCAACTGAAG CACCAGCATGTTGTACC NM_001205313.1 239
Stat2 CTGAAGGAGATGAGTCACATGC GGTGAACTTGTTCCCAGTCTTC NM_019963.1 189
Stat3 ACAACGCTGGCTGAGAAGCTCC TTGTGCTTAGGATGGCCCGCTC NM_213659.3 226
Irf1 GAAGATAGCCGAAGACCT CTTCATCTCCGTGAAGAC NM_001159396.1 205
Irf2 GGTCCTGACTTCAGCTAT TTCTGCGTAGGAAGACAG NM_008391.4 220
Irf5 GTCAAGACGAAGCTCTTTAGCC CTGCTCTACCATGTGGTCTTTG NM_001252382.1 279
Irf7 GTTTACGAGGAACCCTATGCAG GAAGCGTCTCTGTGTAGTGCAG NM_001252601.1 277
Irf9 GCGTTGTAAACCACTCAGACAG CATAGATGAAGGTGAGCAGCAG NM_001159417.1 204
GAPDH TTGTGCAGTGCCAGCCTCGT  TCGGCCTTGACTGTGCCGTT NM_008084.3 214
β-actin ACTGTCGAGTCGCGTCC ATGGCTACGTACATGGCTGG NM_007393.5 487
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tumor associated antigen specific effector CD8+ T cell immune 
responses against cancer cells.
Enhanced activation of Mam‑A specific effector CD8+ 
T lymphocyte mediated cytotoxic responses following treat‑
ment with selenocompounds. As our data demonstrated that 
following MSA and DMDSe treatment there was enhanced 
HLA-A2 expression on THP-1 cells, we next determined 
if this enhanced expression enabled HLA class-I immuno-
dominant MamA2.1 peptide presentation and eventual 
antigen‑specific CD8+ T cell activation leading to cell medi-
ated cytotoxicity against breast cancer cells. We therefore 
stimulated naïve CD8+ T lymphocytes collected from healthy 
HLA-A2+ human subjects with MamA2.1peptide in the pres-
ence of antigen presenting HLA-A2+ THP-1 mononuclear cells 
pre-treated with selenocompounds (Fig. 3A). We collected 
these activated CD8+ T cells by magnetic beads isolation 
and ascertained the purity (>95%) by flow cytometry. We 
investigated if these MamA2.1 activated CD8+ T cells exerted 
higher cytotoxicity against breast cancer cell lines compared 
to activation by THP-1 cells without selenocompound treat-
ment. The breast cancer cell lines (referred to as target cells) 
and MamA2.1 activated CD8+ T cells (referred to as effector 
cells) were co-cultured. The cytotoxic effect was analyzed 
by LDH release assay and measured at various effector to 
target (E:T) ratios (6.25: 1 to 50:1). As shown in Fig. 3B-E, the 
MamA2.1‑specific CD8+ T lymphocytes exerted higher cyto-
toxicity on HLA-A2+/MamA+ AU565 and UACC-812 breast 
cancer cell lines. The CD8+ T cells activated by THP-1 cells 
pre-treated with MSA (72±8%, P<0.05) and DMDSe (66±11%, 
P<0.05) exerted higher cytotoxicity (E:T 50:1) compared 
to non-selenocompound pre-treatment (44±9%). However, 
pre‑treatment with SeMet could not induce any significant 
additional cytotoxicity (46±8%, P>0.05). Furthermore, 
MamA2.1 activated CD8+ T cells did not induce any cytotox-
icity on HLA-A2+/MamA- MCF-7 (Fig. 3D) and MDA-MB-231 
(Fig. 3E) breast cancer cell lines, thus suggesting that the 
MamA2.1 activated CD8+ T cells exerted cytotoxic effector 
functionality on breast cancer cells in Mam‑A antigen‑specific 
manner. Taken together, these data demonstrated that MSA 
and DMDSe induced HLA class I expression leading enhanced 
antigen presentation of immunodominant antigenic peptides 
following potential anti-cancer vaccination leading to breast 
cancer cell elimination.
Increased IFNγ signaling in CD8+ T cells following activa‑
tion by methylselenol producing selenocompound pre‑treated 
THP‑1 cells. As interferon (IFN)-γ signaling plays a critical role 
in cytotoxic CD8+ T lymphocyte responses, we determined the 
expression of IFN signaling molecules. Using methodologies 
Figure 1. HLA-A2 expression in THP-1 cells following treatment with selenocompounds. (A) Schematic of selenocompound metabolism. (B) Production of 
DMSe by THP-1 cells following treatment with SeMet (50 µM), MSA (2.5 µM) and DMDSe (2.5 µM). DMSe could be further methylated to unstable TMSe. 
Pure DMSe at 1 µM in cell culture media was analyzed and used as positive control. (C) HLA-A2 surface expression on THP-1 cells following treatment with 
SeMet (50 µM), MSA (2.5 µM) or DMDSe (2.5 µM). Percent expression was analyzed via isotype labelled negative control antibody staining. (D-F) Dose 
response following treatment (D) SeMet, (E) MSA and (F) DMDSe to assess the expression of HLA-A2. Data are presented as the mean ± SEM (n=4). 
Statistical significance for C, D and E were analyzed via one‑way ANOVA. *P<0.05 vs. 0 µM. HLA, human leukocyte antigen; SeMet, selenomethionine; MSA, 
methylselenic acid; DMDSe, methylselenol derivative dimethyl selenol; TMSe, trimethy selenol; MFI, mean fluorescence intensity.
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described above, we determined the transcript levels of IFN 
signaling molecules in MamA2.1 activated CD8+ T cells at 
4 h following co-culture with AU565 cells at E:T ratio of 50:1. 
As shown in Fig. 4A, CD8+ T cell activation by THP-1 cells 
Figure 2. Expression of components involved in the APM of breast cancer cell lines following treatment with selenocompounds. (A) Western blot analysis and 
(B) mRNA levels of the APM components in THP-1 cells following treatment with SeMet (50 µM), MSA (2.5 µM) or DMDSe (2.5 µM). Data are presented 
as the mean ± SEM (n=4). Statistical significance was determined using a Tukey HSD test compared with non‑treatment conditions. *P<0.05 vs. 0 µM . APM, 
antigen presentation machinery; SeMet, selenomethionine; MSA, methylselenic acid; DMDSe, methylselenol derivative dimethyl selenol; Rel, relative; TAP, 
transporter associated with antigen processing; β2M, β2-microglobulin.
Figure 3. Cytotoxic potential of CTLs following activation by MamA2.1 peptide and co-stimulation with selenocompounds pre-treated THP-1 cells. 
(A) Experimental design schematic. Cytotoxicity of CTLs following activation by MamA2.1 peptide and THP-1 cells pre-treated with SeMet (50 µM), MSA 
(2.5 µM) or DMDSe (2.5 µM) in (B) AU565 (HLA-A2+/Mam-A+), (C) UACC-812 (HLA-A2+/Mam-A+), (D) MCF-7 (HLA-A2+/Mam-A-) and (E) MDA-MB-231 
(HLA-A2+/Mam-A-) cells. E:T ratios of 50:1, 25:1, 12.5:1 and 6.25:1 are presented. Data are presented as the mean ± SEM (n=4). Statistical significance was 
determined via one-way ANOVA. *P<0.05 vs. 0 µM. CTLs, CD8+ T lymphocytes; SeMet, selenomethionine; MSA, methylselenic acid; DMDSe, methylselenol 
derivative dimethyl selenol; HLA, human leukocyte antigen; E:T, effector:target.
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pre-treated with MSA and DMDSe induced higher expression 
of IFN signaling molecules namely, Jak1, Jak2, Stat1, Stat2, 
Stat3, Irf-1, Irf-5, Irf-7 and Irf-9. As these data demonstrated 
there is increased transcript levels of IFN signaling molecules, 
we next determined the secretory IFNγ protein concentration 
in the supernatant obtained from the co-cultures by ELISA. As 
shown in Fig. 4B, ELISA based analysis of the IFNγ protein 
expression in the supernatant collected from the CD8+ T cells 
activated under MSA (1179±127 Pg/ml, P<0.05) and DMDSe 
(983±148 pg/ml, P<0.05) pre-treatment conditions resulted 
in enhanced IFNγ expression compared to no selenocom-
pound pre-treatment (511±73 pg/ml). However, CD8+ T cells 
activated by SeMet pre-treatment conditions (549±91 pg/ml, 
P>0.05) did not induce significant change in IFNγ expres-
sion. Furthermore, we determine the direct effector role of 
the expressed IFNγ on cytotoxic functionality by performing 
blocking studies. As shown in Fig. 4C, blocking with IFNγ 
monoclonal antibodies (mAb) and HLA-A2 mAb signifi-
cantly inhibited the cytotoxicity of MamA2.1 activated CD8+ 
T lymphocytes, thus suggesting that the cytotoxic effector role 
CD8+ T cells is dependent upon selenocompound mediated 
upregulation of IFNγ signaling. Taken together, our current 
data demonstrated that MSA and DMDSe induced HLA class 
I expression and presentation of HLA-A2 restricted antigenic 
epitope for specific peptide vaccine‑like activation of CD8+ 
T cell leading to enhanced breast cancer cell cytotoxicity.
Discussion
Peptide and DNA based cancer vaccines have many advan-
tages, including-being inexpensive, convenient acquisition of 
clinical-grade peptides, easy administration, higher speci-
ficity, potency due to their stronger compatibility with targeted 
proteins, and greater safety with few side effects (20,21). 
Previous studies from our laboratory have demonstrated safety 
and immune efficiency of mammaglobin-A, breast cancer 
specific tumor associated antigen, based DNA vaccine in breast 
cancer patients (16,22). The efficiency of these vaccination 
strategies have limited success as cancer cells downregulate 
surface expression of HLA class I molecules causing loss of 
identification of tumor cells by the host CTLs (23).
While the exact mechanism by which the trace element 
selenium (Se) exerts anti-cancer potential is unknown, our 
current study demonstrates that MSA and DMDSe, synthetic 
selenocompound and precursor of methylselenol, induced 
MHC class I surface expression on professional antigen 
presenting-like THP-1 cells. This data is in line with studies 
from other laboratories which have demonstrated enhanced 
HLA class I expression by these compounds in other cancer 
cell lines such as melanoma cells. In contrast, the SeMet based 
selenocompounds which do not produce methylselenol failed 
to induce HLA class I surface expression. This hypothesis is 
in accordance to results by Hagemann-Jensen et al, where in, 
Figure 4. Upregulation of IFNγ signaling in CTLs following activation by the MamA2.1 peptide and co-stimulation with selenocompound pre-treated THP-1 
cells. (A) Expression of components involved in the IFNγ signaling pathway molecules in CD8+ T cells following activation with MamA2.1 peptide, and in 
THP-1 cells pre-treated with SeMet (10 µM), MSA (2.5 µM) or DMDSe (2.5 µM). (B) Quantity of IFNγ protein secreted in the supernatant following the 
4 h incubation of MamA2.1 activated CTLs and AU565 cells at an E:T ratio of 50:1, as determined via ELISA. (C) Cytotoxicity of CTLs on AU565 at an E:T 
ratio 50:1 upon blocking of IFNγ and HLA‑A2 by specific monoclonal antibodies. (D) Schematic of the mechanism of action of MSA and DMDSe towards 
CTL activation. Data are presented as the mean ± SEM (n=4). Statistical significance between groups were assessed using Tukey HSD pair‑wise comparisons 
(A) and one-way ANOVA for multiple comparisons (B and C)  *P<0.05 vs. 0 µM. IFNγ, interferon-γ; CTLs, CD8+ T lymphocytes; SeMet, selenomethionine; 
MSA, methylselenic acid; DMDSe, methylselenol derivative dimethyl selenol; HLA, human leukocyte antigen; Rel, relative; E:T, effector:target.
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they have shown that MSA and DMDSe mediated upregula-
tion of NKG2D receptor ligands (19).
The antigenic peptides loaded on HLA class I molecules 
and identified by CD8+ T lymphocytes generally originate from 
the degradation of intracellular proteins by proteasomes and 
translocation to the lumen of the endoplasmic reticulum (ER) 
by the transporter associated with antigen processing (TAP)1/2 
heterodimeric complex. Defects in this antigen-processing 
machinery and, in particular, in TAP subunits, have been 
described as a major mechanism used by several tumors to escape 
from CTL attack (24). Evidence for antitumor CTL was provided 
by isolation of tumor-specific CTL from peripheral blood or 
tumor tissue of patients with diverse cancers, such as melanoma 
and lung carcinoma (25). The IFNγ mediated pro‑inflammatory 
mileu is critical for the priming and effector responses by CTLs 
following antigen presentation by HLA class I molecules (26). The 
CTLs can lyse target cells via the perforin granule exocytosis by 
the IFNγ mediated JAK/STAT pathway. In our current study we 
demonstrated that the induction of HLA-A2 by MSA and DMDSe 
was associated with transcriptional upregulation of components 
of the APM, including proteasomal subunits and components of 
the peptide loading complex, along with upregulation of IFNγ 
signaling, such as the upregulation of JAK/STAT/IRF molecules.
Our current study is limited to testing HLA class I expres-
sion in mononuclear tumor-infiltrating antigen presenting 
macrophage‑like cells. However, the exact efficiency of seleno-
compounds towards HLA expression on cancer cells could not 
be tested in our current in vitro system. In an in vitro system 
cancer cell lines already had enhanced cell surface expression 
of HLA class I molecules. To directly test this effect of seleno-
compounds on cancer cells, would require in vivo based studies 
in murine or other small animal tumor models. Further we have 
currently utilized peptide-based model to study adjuvant effect 
of selenocompounds, however, future studies with Mam-A 
DNA-vaccine based model should be utilized to study the 
adjuvant effect of selenocompounds on DNA-based anti-cancer 
vaccines. Future studies utilizing in vivo model will provided a 
stronger evidence for human clinical application.
In conclusion, our data provides a new adjuvant approach 
to further potentiate anti-cancer vaccine strategies. Further, we 
have demonstrated that MSA and DMDSe could upregulate 
the MHC class I expression in cancer cells which would enable 
anti-cancer vaccine induced activated CTLs to inhibit tumor 
immune-evasion and promote cancer immune-elimination. 
Therefore, we think novel anti-cancer strategies utilizing inclu-
sion of MSA and DMDSe will improve vaccine therapeutic 
outcomes by enhancing CTL mediated immune-surveillance 
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